AG-73305

AG-73305 is a humanized, bi-specific Fc-fusion protein developed for the treatment of retinal diseases such as diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), and retinal vein occlusion (RVO). The drug is designed to simultaneously block vascular endothelial growth factors (VEGFs) and integrins by combining a VEGF-trap with a disintegrin domain that inhibits key integrin receptors. This dual mechanism targets multiple pathways involved in retinal disease pathogenesis, aiming to provide improved efficacy and durability compared to current therapies. AG-73305 is administered via intravitreal injection and has shown promising safety and efficacy results in early-phase clinical trials, including improvements in best corrected visual acuity (BCVA) and central subfield thickness (CST)[1][3][4][5][6][9][10].

Other names

Anti-VEGF/disintegrin fusion protein